Identity
- Security key
- 21823
- Ticker
- SNDX
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2016-03-03
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- SNDX
Detail
Enriched 2026-08-14 20:47
- Market cap
- $1,768,082,302.8
- Shares outstanding (class)
- 88,610,027
- Shares outstanding (weighted)
- 89,297,086
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 298
- Location
- NEW YORK, NY
- Homepage
- https://www.syndax.com
- Description
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Market cap and share counts drift.